Halometasone

Halometasone
Clinical data
Trade names	Sicorten
Other names	(6S,8S,9R,10S,11S,13S,16R,17R)-2-chloro-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxy-acetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
AHFS/Drugs.com	International Drug Names
Routes of; administration	Topical
ATC code	D07AC12 (WHO) ;
Identifiers
	IUPAC name (6α,11β,16α)-2-Chloro-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione;
CAS Number	50629-82-8 ;
PubChem CID	9846332;
ChemSpider	8022046 ;
UNII	J69Z9UU41Z;
ChEMBL	ChEMBL1587228 ;
CompTox Dashboard (EPA)	DTXSID1048382 ;
ECHA InfoCard	100.051.496
Chemical and physical data
Formula	C22H27ClF2O5
Molar mass	444.90 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(CO)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)C(\Cl)=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@H]3C)C)C;
	InChI InChI=1S/C22H27ClF2O5/c1-10-4-11-12-5-15(24)13-6-16(27)14(23)7-19(13,2)21(12,25)17(28)8-20(11,3)22(10,30)18(29)9-26/h6-7,10-12,15,17,26,28,30H,4-5,8-9H2,1-3H3/t10-,11+,12+,15+,17+,19+,20+,21+,22+/m1/s1 ; Key:GGXMRPUKBWXVHE-MIHLVHIWSA-N ;
	(what is this?) (verify)

Halometasone is a potent (Group III) synthetic tri-halogenated corticosteroid for topical application possessing pronounced anti-inflammatory, antiexudative, antiepidermoplastic, antiallergic, and antipruritic properties. It has been approved in many European countries including Spain, Germany, Switzerland, Austria, Netherlands, Belgium, and Portugal and other regions such as China, Hong Kong, Turkey, Israel, South Africa and India.

It has been used to treat chronic psoriasis vulgaris^[1] and non-infected acute eczematous dermatoses (eczema).^[2] One study demonstrated that 0.05% halometasone cream was more effective than 0.05% betamethasone cream in treating dermatitis, though both were well tolerated, with no systemic adverse effects reported.^[3]

References

↑ Galbiati G, Bonfacini V, Candiani F (1983). "Halometasone cream by day and halometasone ointment at night for the treatment of patients with chronic psoriasis vulgaris". The Journal of International Medical Research. 11 Suppl 1: 31–3. PMID 6339290.
↑ Yawalkar SJ, Macarol V, Montanari C (1983). "An overview of international clinical trials with halometasone cream". The Journal of International Medical Research. 11 Suppl 1: 1–7. PMID 6339286.
↑ Schuppli R, Dressler H, Yawalkar SJ, Weirich EG (February 1983). "[Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate]". Zeitschrift für Hautkrankheiten. 58 (4): 230–7. PMID 6342285.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Galbiati G, Bonfacini V, Candiani F (1983). "Halometasone cream by day and halometasone ointment at night for the treatment of patients with chronic psoriasis vulgaris". The Journal of International Medical Research. 11 Suppl 1: 31–3. PMID 6339290.

[2] Yawalkar SJ, Macarol V, Montanari C (1983). "An overview of international clinical trials with halometasone cream". The Journal of International Medical Research. 11 Suppl 1: 1–7. PMID 6339286.

[3] Schuppli R, Dressler H, Yawalkar SJ, Weirich EG (February 1983). "[Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate]". Zeitschrift für Hautkrankheiten. 58 (4): 230–7. PMID 6342285.

[1]

[2]

[3]